Search General Info
Search Education
Search Partnering Companies
Wayland Biotherapeutics (WBTx) designs and develops proprietary biotherapeutics that are human in nature and that inhibit human infection by a variety of pathogenic enveloped RNA viruses including SARS-CoV-2, the causative agent of the current COVID-19 pandemic.
WBTx is pursuing a project that encompasses a host-derived, broad-spectrum antiviral agent that will block the infectivity of SARS-CoV-2. The basic concept is to generate a recombinant “receptor decoy” molecule that binds with high affinity or avidity to the virus and blocks its ability to enter cells, thus halting the infectious trajectory in that patient. The “decoy” in this construct is based upon the canonical lymphocyte antigen-6/urokinase-type plasminogen activator receptor [Ly6/uPAR] family protein, lymphocyte antigen 6 complex, locus E (LY6E). Ly6E, a interferon-stimulated gene (ISG), is known to restrict SARS-CoV-1 and SARS-CoV-2, blocking viral infection of all known human coronaviruses.
WBTx is pursuing a project that encompasses a host-derived, broad-spectrum antiviral agent that will block the infectivity of SARS-CoV-2. The basic concept is to generate a recombinant “receptor decoy” molecule that binds with high affinity or avidity to the virus and blocks its ability to enter cells, thus halting the infectious trajectory in that patient. The “decoy” in this construct is based upon the canonical lymphocyte antigen-6/urokinase-type plasminogen activator receptor [Ly6/uPAR] family protein, lymphocyte antigen 6 complex, locus E (LY6E). Ly6E, a interferon-stimulated gene (ISG), is known to restrict SARS-CoV-1 and SARS-CoV-2, blocking viral infection of all known human coronaviruses.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Massachusetts
Company HQ Country:
United States
Year Founded:
2020
Main Therapeutic Focus:
Infectious Diseases
Lead Product in Development:
LY6E Decoy Receptors
Development Phase of Primary Product:
Discovery
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
Biotechnology Innovation Organization
1201 New York Avenue NW, Suite 1300, Washington, DC, 20005 ・ 202-962-9200
© BIO 2024 All Rights Reserved